Larry Wood: Yeah. Thanks, Danielle. I think clinical trial enrollment, I think, is always an important marker for the opportunity. And I think having rapid clinical trial enrollment, I think, does certainly speak to that opportunity. I think it also speaks to the fact that everything we’ve done in the PARTNER series of trial has still been just isolated to severe aortic stenosis. And most of that work is, is it better to do surgeries or better to do TAVR. What I think there’s a lot of enthusiasm and excitement about now is actually attacking the disease in a different way and saying, should we be waiting until patients are literally at the end stage before we even consider doing anything, or should we be evaluating those patients sooner.
And I think that could have two benefits. The first is, if we showed that treating moderate patients is important and has real advantages for those patients, then I think it could provide a real accelerant for those severe patients that aren’t moving today. And I think we’ve seen that when we went from high risk to intermediate risk, we have the intermediate risk approvals, one of the biggest accelerations we saw was in the high-risk space. Because people are like, for having to debate in the intermediate, then high risk are automatic at this point. But I think the other thing about it is if we can show a benefit in these moderate patients, there’s literally twice as many moderate patients as there are severe patients. And so, when we think about long-term and just continual opportunities to drive the market, I think that steady cadence of data with early TAVR coming later this year at TCT, and then we’re talking about a couple of years, two and a half years later, we get the PROGRESS trial, that steady cadence of data, we think is going to be important for informing patients and improving treatment rates.
Danielle Antalffy: That makes sense. I’ll leave it at that. Thanks so much, guys.
Bernard Zovighian: So, in closing, I am very proud about what we did last year. 2023 was a great year. Strong performance across our four product groups globally. When I think about this year 2024, I’m super excited. We are going to have multiple breakthrough technologies, clinical trial in TAVR, TMTT and surgical. Here, we have a chance. The same way we did it in TAVR 20 years ago to shape the TMTT space with EVOQUE and providing basically a toolbox to physician to treat so many patients. So, that’s a very unique opportunity that we are taking very seriously. The speed of critical care, we are executing on this one also in 2024. So I’m super confident that this year is going to be a super exciting year and we are going to be very well positioned to accelerate growth in 2025 and beyond. So with that, thanks for your continued interest in Edwards. Scott, Mark and I welcome any additional questions by telephone. Thank you, everyone.
Operator: Thank you. This concludes today’s conference. All parties may now disconnect.
